The Honest Dose #18

As I’m sure you all know when you’re “peptide-curious” like myself you end up spending a lot of time explaining to people what a peptide is before you can explain why any of it matters, and that gap is just part of operating at the edge of something before it becomes mainstream.

But then Chainalysis, the firm that maps cryptocurrency flows for financial institutions, law enforcement, and governments, published a report this summer showing that the gray-market peptide ecosystem is now processing cryptocurrency at a run rate that is on pace to cross one hundred million dollars annually in 2026. That number has since appeared in mainstream financial press, health policy coverage, and pharma trade publications. The thing I thought of as a niche corner of biohacking culture is now being cited in the same conversations as crypto inflow analysis and global illicit trade patterns.

I don’t say that with alarm but with something closer to genuine fascination, because the trajectory of how a thing moves from fringe to mainstream is almost never a straight line, and this one took a route nobody drew on a map. GLP-1s were the first bridge. Semaglutide and tirzepatide turned the phrase "research peptide" from a gym-locker term into something that gets mentioned in the Wall Street Journal and on the floor of the Senate, because the compounds people were sourcing from gray-market vendors were the same molecules millions of people were being prescribed through their doctors. That collision between a regulated pharmaceutical story and an underground supply chain was always going to get noticed. What I did not fully anticipate was how quickly the financial infrastructure underneath the gray market would become its own story.

Six consecutive quarters of growth. Forty-six percent of inflows touching privacy-enhancing tools to obscure the trail. A wave of vendor shutdowns and enforcement actions large enough to qualify as a beat for investigative journalists who cover neither health nor technology as their day job, but financial crime. That is where this space sits right now, and I think it is worth spending an issue pulling on that thread a little, because the number obscures as much as it reveals, and the enforcement wave does not mean what the headlines tend to imply.

Let's get into it.

For some time now the gray market was something you had to be inside to see. This month it became something you can read about in mainstream financial, medical, and regulatory news, all in a few weeks of each other. Three separate stories broke that, taken together, describe the same phenomenon from three angles: the money, the outcomes, and the enforcement. Here they are.

The money: a $100 million-plus run rate, running entirely on crypto. Chainalysis published on-chain data (report dated June 4) tracking cryptocurrency flowing into gray-market peptide vendors. For most of 2024 that flow sat at roughly $1 million per quarter. In the first quarter of 2026 it jumped 159% in a single quarter, from $12 million to $32 million, and it is on pace for about $39 million in Q2, six consecutive quarters of growth and firmly across a $100 million-plus annual run rate. The industry migrated to crypto because banks and card processors will not touch these sales, so the entire industry migrated to Bitcoin and stablecoins. Chainalysis tied the takeoff to two forces, the broader "Make America Healthy Again" moment and, in late 2025, a collision with the "looksmaxxing" subculture on TikTok. And something I found rather interest; they traced some vendors back to Chinese labs that previously supplied fentanyl and amphetamine precursors and moved into peptides for the better margins and the lighter legal risk.

The number under the number: independent testing spend fell 88%. In the same dataset, Chainalysis found that average spending on independent purity testing fell 88% per buyer even as purchase volume exploded. More people are buying, and each of them is verifying far less than buyers used to. The market is scaling and its own quality-control habit is collapsing at the same time. That is the opposite of what you would want to see in a market this young, and it sets up the third story well.

The outcomes: gray-market retatrutide underperformed the trials by about half. In late August, researchers at a Massachusetts data-analytics firm released a study, still in peer review, that did something clever. Because retatrutide is not approved, it has no prescription record anywhere in the health system, so the only trace of who is using it lives in the free-text notes physicians type into charts. The team mined de-identified records, found hundreds of confirmed gray-market users, and matched them against trial participants. The gray-market group lost roughly half the weight the trial participants did over comparable windows, on the order of 4.7%, 5.3%, and 7.2% at three, six, and twelve months, against 5.7%, 11.9%, and 15.5% for trial participants, while still showing elevated cardiovascular effects. The likely explanation is exactly what the testing-spend collapse predicts: gray-market product is frequently not the strength printed on the label, and is sometimes not even the same molecule.

The enforcement: the sellers are thinning out. Around all of this, regulatory pressure has kept escalating. Over the past year the FDA moved from a wave of fifty-plus warning letters to warehouse actions and support for criminal prosecutions, and a string of the largest names in the category closed, some voluntarily, some under prosecution, some quietly. Just this month the agency issued fresh warning letters to several more sellers for marketing unapproved peptides as drugs for human use. The practical result is consolidation: fewer, larger vendors, and a higher premium on being able to independently verify what you are buying. Which is, again, the same thread. The market is getting smaller and harder to read at the exact moment its buyers are verifying less.

Put together, the picture is coherent and a little unsettling. Demand is at an all-time high, the money has gone fully underground, verification is cratering, the products underperform the reputation they borrow, and the sellers are being winnowed by enforcement. None of these is a reason to panic. All of them together are a reason to be more careful, precisely when the cultural momentum is telling you the opposite.

Read the full retatrutide profile

The claim: The wireless world is quietly cooking you, and the fix is to reduce your exposure to the electromagnetic fields coming off your phone, your wifi router, 5G towers, smart meters, and "dirty electricity." Ideally you reduce it with the help of products built for the job: shielded phone cases, EMF-blocking pendants and stickers, faraday bags, grounding mats, canopy nets for the bed. The promised payoff runs the full wellness stack, better sleep, fewer headaches, more energy, and protection from cancer somewhere down the line.

The reality: This one mixes real science with mostly-imported fear, and the two get sold to you as a single thing.

Start with the conflation the whole category rests on. "Radiation" is doing enormous work in the marketing, and it is borrowing its menace from the wrong kind. Ionizing radiation, meaning X-rays, gamma rays, carries enough energy to knock electrons off atoms and damage DNA directly. The radio-frequency EMF coming off your phone and router is non-ionizing. It does not carry the energy to break those bonds. That is not a marketing distinction, it is a physics one, and the main fact in this entire discussion. The word "radiation" invites you to picture one thing while the devices emit a categorically different thing.

At high enough intensity, RF (radio frequency) energy heats tissue. That thermal effect is well understood, and it’s why national exposure limits exist in the first place. Consumer devices are engineered to operate far below the level where any meaningful heating occurs. So the mechanism the safety rules are actually built around is not in dispute, and it is also not the one the pendants claim to protect you from.

The real scientific question is whether non-thermal, long-term, low-level exposure does anything. The largest and most current answer comes from a 2024 systematic review commissioned by the WHO, which worked through more than 5,000 studies and concluded there is no association between mobile phone use and brain or other head cancers, including among heavy users and people who have used phones for more than a decade. Its authors describe it as the strongest evidence to date that wireless radio frequency is not a human health hazard. It should be noted a vocal minority of researchers argues that review understated the risk and points to analyses where the heaviest, longest-term users showed elevated tumor signals. That dispute is real and ongoing. But the honest summary of where the weight of evidence sits, according to the bodies that review all of it is there is no demonstrated hazard at the exposure levels consumer devices produce, with research continuing at the margins.

Now the products, which is where the claim tips from overstated into backwards. Most consumer EMF-blocking gear, does nothing measurable, and that has been shown over and over. Worse, the ones that actually do block signal can make things slightly worse, because a phone that cannot reach a tower turns its power up to compensate, which raises the local emission the case was sold to reduce. So a real slice of this market is selling you either an inert object or a device that nudges the exact number it advertises in the wrong direction.

The honest version of the claim: The consensus of the largest reviews is that consumer-level exposure has not been shown to harm you, a minority of scientists disputes that, and the research is not finished. If you would personally rather reduce your exposure while that plays out, the moves that work cost nothing: use earbuds or speakerphone, do not sleep with the phone on your pillow, keep the router out of the bedroom. The pendants and stickers and shielded cases are selling you the feeling of control, and occasionally the opposite of the protection on the label. It is the same shape as the gray market up top, just flipped. There, people are under-worried about a risk you can actually measure. Here, people are over-worried about one you mostly cannot, and buying products for it either way. The whole game, in both directions, is calibration.

Retatrutide is a clean illustration of why PeptideClear runs two separate scores instead of one, so I want to use this week's news to show the seam between them.

On research quality, retatrutide scores well. Its RQS sits at 77, in the Moderate band. That number reflects a genuinely strong trial program: large, randomized, placebo-controlled Phase 3 studies with striking, peer-reviewed results.

And yet the study I described above found gray-market users getting about half the trial benefit. How do both facts live in the same molecule? Because they answer two different questions, and this is the reason the RQS is not a buying signal and never can be. The RQS asks how good the research on a compound is. It does not, and cannot, ask whether the specific unbranded vial someone bought with Bitcoin actually contains that compound, at that strength, without contaminants. That second question is a different axis, and it is the one the Vendor Transparency Score exists to probe. VTS grades vendors purely on verifiable documentation practices, third-party testing, batch traceability, whether a stranger can actually pull a certificate of analysis, how recent that testing is. It scores process inputs only. It is not a safety verdict, not an efficacy verdict, and not an endorsement of any vendor, and a high VTS number never means "this is safe to use." It means "this vendor lets you verify more of what they are selling."

Hold the two together and the retatrutide news snaps into focus. Excellent research quality, the RQS, tells you the molecule is worth taking seriously. Weak or absent vendor transparency, the VTS, tells you why the trial results did not follow the molecule into the gray market. The 88% collapse in independent testing is the population-level version of the same gap: buyers trusting the RQS-style story about the compound while skipping the VTS-style verification of the actual product. Great science and an unverifiable vial can absolutely coexist, and this weeks issue highlights exactly this.

See how the Vendor Transparency Score works

The survivors are the safe ones" is the narrative to distrust. The enforcement wave is real and consolidation is happening. The vendors still standing will increasingly frame their own survival as proof of quality, as in "we are the ones who made it through the crackdown." Surviving enforcement is not the same as documenting your product, and neither is longevity. The only thing that tells you what is in a vial is verifiable testing, not a vendor's body count.

The 88% testing-spend collapse is the stat to keep your eye on. Everyone is going to quote the $100 million. The number I would watch is the one underneath it. A market that buys more while verifying less is building fragility in real time, and it is the mechanism behind the retatrutide outcome gap. If that trend reverses, it is the healthiest sign the space could show. If it keeps falling, expect more studies like August's.

Hold the retatrutide study at the right resolution. It is directionally important and methodologically limited. Mining physician free-text is a clever way to see an otherwise invisible population, and it is also not a randomized controlled trial, the sample is only what happened to leak into charts, and it is still in peer review. So it is strong enough to take seriously and soft enough that it will get over-cited by people warning you off and dismissed by people selling to you. The calibrated read is in the middle: real signal, early evidence.

Hopefully that was helpful/interesting, see you next week.

-Emeka

Peptidclear.com

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.